Oseltamivir phosphate ke setlhare se thibelang likokoana-hloko se sebelisoang ho phekola tšoaetso e matla ea ntaramane ho batho ba baholo, bacha le bana (≥ libeke tse 2 tsa lilemo). Oselavir® e tla fumaneha Chaena ka foromo ea litekanyetso - 12.5ml: 75mg phofo bakeng sa ho emisoa ka molomo.
WHO e hakanya hore ntaramane ea linako tsa selemo e ka ’na ea fella ka ho shoa ha batho ba 290,000 650,000-1 XNUMX selemo le selemo ka lebaka la mafu a matšoafo feela. Khakanyo ha e nahane ka lefu le bakoang ke mafu a mang a kang lefu la pelo le methapo ea mali, e ka amanang le ntaramaneXNUMX.
Dr. Vamsi Krishna Bandi, Motsamaisi oa Tsamaiso, Hetero Group of Companies o itse, "Re thabetse hore Hetero e sebelisane le Shenzhen Beimei Pharmaceuticals, Chaena, e fumane tumello ea Oselavir® (Oseltamivir) Chaena. Ena ke tumello ea pele ea sehlahisoa sa Hetero naheng ea China, 'me re ikemiselitse ho tlisa lihlahisoa tse ngata Chaena haufinyane. ”
Mme Guangmei Wu, Mopresidente le CEO oa Shenzhen Beimei Pharmaceuticals o itse, "Ka ho tšepana le tšehetso pakeng tsa lihlopha tsa Beimei le Hetero, Oselavir® e ile ea thakholoa Chaena e le sehlahisoa sa pele sa China se amohetsoeng sa Oseltamivir ka foromo ea litekanyetso tse khethehileng tsa bana. Ke leboha sehlopha sa Hetero bakeng sa mosebetsi o boima le boiteko ba bona ts'ebetsong eohle ea tlhahiso ea lihlahisoa, kopo ea ho ngolisa le ho lokisetsa ho qala Oselavir®. Re labalabela ho hlahloba lihlahisoa tse ngata le Hetero bakeng sa tlhokomelo ea bophelo bo botle ba bana nakong e tlang. ”
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- This is the first finished product approval for Hetero in China, and we are committed to bring more products to China in the near future.
- I express gratitude to the Hetero team for their hard work and effort in the whole process of product development, registration application and launch preparation for Oselavir®.
- Guangmei Wu, President and CEO of Shenzhen Beimei Pharmaceuticals said, “With mutual trust and support between Beimei and Hetero teams, Oselavir® was launched in China as the first Chinese approved Oseltamivir product in paediatric-specific dosage form.
